Tag Archives: Sangamo

May, 2017

17 May
Sangamo’s Hemophilia A Gene Therapy Candidate Receives Fast Track Status from the FDA

RICHMOND, Calif., May 16, 2017 /PRNewswire/ — Sangamo Therapeutics, Inc. (NASDAQ: SGMO) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SB-525, the Company’s clinical stage cDNA gene therapy candidate for hemophilia A, which is being developed as part of an exclusive, global …
Share
5 May
Three Sangamo Clinical Programs Receive Special Regulatory Designations from the FDA

RICHMOND, Calif., May 4, 2017 /PRNewswire/ — Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) of special regulatory designations for three of the Company’s clinical programs. Rare Pediatric Disease (RPD) designation …
Share

8 February
FDA Clears Sangamo Biosciences’ IND Application of SB-318 for Treatment of MPS I

RICHMOND, Calif., Feb. 8, 2016 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type …
Share